Author:
Nishimura Jun-ichi,Kawaguchi Tatsuya,Ito Shuichi,Murai Hiroyuki,Shimono Akihiko,Matsuda Takahisa,Fukamizu Yuji,Akiyama Hirozumi,Hayashi Hideo,Nakano Takashi,Maruyama Shoichi
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804–11. https://doi.org/10.1182/blood-2014-02-522128.
2. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25(11):1256–64. https://doi.org/10.1038/nbt1344.
3. Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996;33(17–18):1389–401. https://doi.org/10.1016/s0161-5890(96)00078-8.
4. SOLIRIS® (eculizumab) 300 mg for intravenous infusion. Interview Form, revised December 2020 (16th edition). Available from https://soliris.jp/-/media/soliris_jp/document-slide/interview_form.pdf. Accessed 19 July 2023. [In Japanese].
5. Fakhouri F, Loirat C. Anticomplement treatment in atypical and typical hemolytic uremic syndrome. Semin Hematol. 2018;55(3):150–8. https://doi.org/10.1053/j.seminhematol.2018.04.009.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献